z-logo
open-access-imgOpen Access
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
Author(s) -
Emma C. Thomson,
Laura E. Rosen,
James G. Shepherd,
Roberto Spreafico,
Ana da Silva Filipe,
Jason A. Wojcechowskyj,
Christopher Davis,
Luca Piccoli,
David J. Pascall,
Josh R. Dillen,
Spyros Lytras,
Nadine Czudnochowski,
Rajiv Shah,
Marcel Meury,
Natasha Jesudason,
Anna De Marco,
Kathy Li,
Jessica Bassi,
Áine O’Toole,
Dora Pinto,
Rachel Colquhoun,
Katja Culap,
Ben Jackson,
Fabrizia Zatta,
Andrew Rambaut,
Stefano Jaconi,
Vattipally B. Sreenu,
Jay C. Nix,
Ivy Zhang,
Ruth F. Jarrett,
William G. Glass,
Martina Beltramello,
Kyriaki Nomikou,
Matteo Samuele Pizzuto,
L. Tong,
Elisabetta Cameroni,
Tristan I. Croll,
Natasha Johnson,
Julia di Iulio,
Arthur Wickenhagen,
Alessandro Ceschi,
Aoife M. Harbison,
Daniel Mair,
Paolo Ferrari,
Katherine Smollett,
Federica Sallusto,
Stephen Carmichael,
Christian Garzoni,
Jenichols,
Massimo Galli,
Joseph Hughes,
Agostino Riva,
Antonia Ho,
Marco Schiuma,
Malcolm G. Semple,
Peter Openshaw,
Elisa Fadda,
J. Kenneth Baillie,
John D. Chodera,
Suzannah J. Rihn,
Samantha Lycett,
Herbert W. Virgin,
Amalio Telenti,
Davide Corti,
David L. Robertson,
Gyorgy Snell
Publication year - 2021
Publication title -
cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 26.304
H-Index - 776
eISSN - 1097-4172
pISSN - 0092-8674
DOI - 10.1016/j.cell.2021.01.037
Subject(s) - biology , spike (software development) , immunity , covid-19 , spike protein , antibody , virology , genetics , immune system , disease , outbreak , medicine , management , pathology , infectious disease (medical specialty) , economics
Summary SARS-CoV-2 can mutate and evade immunity, with consequences for efficacy of emerging vaccines and antibody therapeutics. Here, we demonstrate that the immunodominant SARS-CoV-2 spike (S) receptor binding motif (RBM) is a highly variable region of S and provide epidemiological, clinical, and molecular characterization of a prevalent, sentinel RBM mutation, N439K. We demonstrate N439K S protein has enhanced binding affinity to the hACE2 receptor, and N439K viruses have similar in vitro replication fitness and cause infections with similar clinical outcomes as compared to wild type. We show the N439K mutation confers resistance against several neutralizing monoclonal antibodies, including one authorized for emergency use by the US Food and Drug Administration (FDA), and reduces the activity of some polyclonal sera from persons recovered from infection. Immune evasion mutations that maintain virulence and fitness such as N439K can emerge within SARS-CoV-2 S, highlighting the need for ongoing molecular surveillance to guide development and usage of vaccines and therapeutics.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom